Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

2.6K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.6K
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

147
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
147
Antimicrobial Proteins01:23

Antimicrobial Proteins

3.9K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence, Clinical Characteristics, and Therapeutic Underachievement in Familial Hypercholesterolemia: Results from the GRegistry-FH Population-Based Study in Greece.

Journal of clinical medicine·2026
Same author

HBV pgRNA induces chronic inflammation in an IL-1β-dependent manner.

Frontiers in immunology·2026
Same author

Anakinra for recurrent pericarditis: a retrospective evaluation of long-term effectiveness, initiation timing and tapering.

Rheumatology international·2026
Same author

Disease-related and psychosocial factors associated with difficult-to-manage and treatment-refractory axial spondyloarthritis: insights from the Greek AxSpA Registry.

Rheumatology international·2026
Same author

The Gut-Immune Axis in Treated HIV Infection: From Mucosal Damage to Chronic Inflammation and Therapeutic Opportunities-A Clinician-Oriented Narrative Review.

Microorganisms·2026
Same author

Bridging the gap in familial hypercholesterolaemia detection: the EPIRUS familial hypercholesterolaemia reverse cascade project as a model for paediatric and family-based screening.

Cardiology in the young·2026

Related Experiment Video

Updated: Sep 1, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.1K

Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.

Panagiotis Skendros1, Georgios Germanidis2, Dimitrios C Mastellos3

  • 1First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.

Science Advances
|August 17, 2022
PubMed
Summary

AMY-101, a complement C3 inhibitor, shows promise in treating severe COVID-19 by reducing inflammation and improving oxygenation. Further trials are warranted to explore its therapeutic potential.

More Related Videos

Quantifying the Effects of Antimicrobials on In vitro Biofilm Architecture using COMSTAT Software
06:18

Quantifying the Effects of Antimicrobials on In vitro Biofilm Architecture using COMSTAT Software

Published on: December 14, 2020

3.5K
Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
06:03

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16

Published on: July 15, 2019

8.0K

Related Experiment Videos

Last Updated: Sep 1, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.1K
Quantifying the Effects of Antimicrobials on In vitro Biofilm Architecture using COMSTAT Software
06:18

Quantifying the Effects of Antimicrobials on In vitro Biofilm Architecture using COMSTAT Software

Published on: December 14, 2020

3.5K
Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
06:03

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16

Published on: July 15, 2019

8.0K

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Complement C3 activation is implicated in severe COVID-19 pathogenesis.
  • Targeting C3 presents a potential therapeutic avenue for COVID-19.

Purpose of the Study:

  • To evaluate the safety and efficacy of AMY-101, a C3 inhibitor, in patients with severe COVID-19.
  • To assess the impact of C3 inhibition on clinical outcomes and biomarkers.

Main Methods:

  • Interim analysis of the ITHACA randomized trial.
  • Comparison of AMY-101 (n=16) versus placebo (n=15) in severe COVID-19 patients.
  • Assessment of oxygen independence, inflammatory markers (CRP, ferritin), and complement activation.

Main Results:

  • AMY-101 was safe and well-tolerated.
  • A higher proportion of AMY-101 patients achieved oxygen independence by day 14 (81.3% vs 53.3%).
  • AMY-101 significantly reduced CRP and ferritin, and inhibited thrombin and NET generation; responders showed complete C3 inhibition.

Conclusions:

  • C3 inhibition with AMY-101 demonstrates potential in severe COVID-19.
  • Non-responders suggested alternative C3 activation pathways, necessitating further investigation.
  • Larger trials are recommended to confirm efficacy and explore C3 inhibition in other complement-mediated diseases.